Trial Profile
A clinical study of AAV-CNGA3
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 21 Aug 2018
Price :
$35
*
At a glance
- Drugs Aguracingene cadoparvovec (Primary)
- Indications Colour vision defects
- Focus Therapeutic Use
- 21 Aug 2018 New trial record
- 08 Aug 2018 According to a MeiraGTx media release, this study is expected to start in early 2019.